News List

Insomnia and schizophrenia innovative treatments approved
2020-02-04

Dayvigo (lembroexant) developed by Eisai is an orexin receptor antagonist. Orexin is a neuropeptide

First oral small molecule CGRP receptor inhibitor approved today for the treatment of migraine
2020-01-10

Recently, the US FDA announced that it has approved the listing of the calcitonin gene-related pepti

Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
2019-12-21

Novartis recently announced topline results from its pivotal global Phase III LUSTER-11and LUSTER-22

Roche T + A immunotherapy research achieves historic breakthrough
2019-12-12

November 22, 2019, Roche announces data from positive studies of the IMbrave 150 phase III clinical

Hansoh pharm's first sorts of new medicine "Flumatinib" will be approved for listing
2019-11-20

Flumatinib is a tyrosine kinase inhibitor and it’s a second-generation TK inhibitor drug against Bcr

FDA approves Lilly Reyvow
2019-10-21

Recently, Lilly announced that the US FDA approved the company's development of Reyvow (lasmidit

The third anti-tb drug was approved by the FDA
2019-09-24

On August 14th, the FDA approved TB Alliance new fluorine-containing anti-tuberculosis drug Pretoman

Holiday Notice of Mid-Autumn Festival
2019-09-11

To all departments and all employees:According to the related provisions on national holidays &

CPhI North America 2020 in Philadelphia USA Booth#1506
2019-08-26

FluoroPharm will exhibit CPhI North America 2020 in Pennsylvania Convention Center,Philadelphia, PA,

FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor
2019-08-19

The U.S. Food and Drug Administration today granted accelerated approval to Rozlytrek (entrectinib),